ANAPTYSBIO, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M | $75.0M | $8.0M | $5.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $88.8M | $98.5M | $80.0M | $99.3M | $56.2M |
| SG&A Expense | $50.7M | $42.4M | $41.9M | $36.6M | $21.5M | $18.9M | $16.1M | $15.5M |
| Operating Income | $47.9M | $-114.9M | $-164.4M | $-115.2M | $-56.8M | $-23.9M | $-107.4M | $-66.7M |
| Operating Margin | 20.4% | -125.9% | -958.3% | -1,119.4% | -89.9% | -31.8% | -1,342.9% | -1,334.4% |
| Interest Expense | — | — | — | — | $0 | $0 | $1.0M | $1.7M |
| Pretax Income | $-13.1M | $-145.2M | $-163.6M | $-128.7M | $-57.8M | $-19.9M | $-97.5M | $-61.8M |
| Income Tax Expense | $164.0K | $3.0K | $-4.0K | $24.0K | $0 | $0 | $-152.0K | $-192.0K |
| Net Income | $-13.2M | $-145.2M | $-163.6M | $-128.7M | $-57.8M | $-19.9M | $-97.3M | $-61.7M |
| Net Margin | -5.6% | -159.1% | -953.7% | -1,251.3% | -91.5% | -26.6% | -1,216.7% | -1,233.1% |
| EPS (Basic) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 |
| EPS (Diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 |
| Shares Outstanding (Basic) | 28.8M | 28.4M | 26.9M | 28.2M | 27.4M | 27.3M | 27.1M | 26.9M |
| Shares Outstanding (Diluted) | 28.8M | 28.4M | 26.9M | 28.2M | 27.4M | 27.3M | 27.1M | 26.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |